You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

~ Buy the ZYKADIA (ceritinib) Drug Profile, 2024 PDF Report in the Report Store ~

ZYKADIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zykadia patents expire, and when can generic versions of Zykadia launch?

Zykadia is a drug marketed by Novartis and is included in two NDAs. There are seven patents protecting this drug.

This drug has two hundred and eighty-five patent family members in fifty-four countries.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.

DrugPatentWatch® Generic Entry Outlook for Zykadia

Zykadia was eligible for patent challenges on April 29, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 18, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for ZYKADIA
International Patents:285
US Patents:7
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 98
Clinical Trials: 11
Patent Applications: 761
Drug Prices: Drug price information for ZYKADIA
What excipients (inactive ingredients) are in ZYKADIA?ZYKADIA excipients list
DailyMed Link:ZYKADIA at DailyMed
Drug patent expirations by year for ZYKADIA
Drug Prices for ZYKADIA

See drug prices for ZYKADIA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZYKADIA
Generic Entry Dates for ZYKADIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for ZYKADIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZYKADIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Plateforme labellisée Inca – Institut Bergonié, BordeauxPhase 3
Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, ParisPhase 3
Commissariat A L'energie AtomiquePhase 3

See all ZYKADIA clinical trials

US Patents and Regulatory Information for ZYKADIA

ZYKADIA is protected by seven US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZYKADIA is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZYKADIA

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Methods of using ALK inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propan- e-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting ZYKADIA

TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷  Try a Trial

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZYKADIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis ZYKADIA ceritinib TABLET;ORAL 211225-001 Mar 18, 2019 ⤷  Try a Trial ⤷  Try a Trial
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 ⤷  Try a Trial ⤷  Try a Trial
Novartis ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ZYKADIA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Zykadia ceritinib EMEA/H/C/003819
Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.
Authorised no no no 2015-05-06
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ZYKADIA

When does loss-of-exclusivity occur for ZYKADIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 4309
Estimated Expiration: ⤷  Try a Trial

Patent: 2395
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 11343775
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2013015000
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 21102
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 13001723
Estimated Expiration: ⤷  Try a Trial

China

Patent: 3282359
Estimated Expiration: ⤷  Try a Trial

Patent: 4262324
Estimated Expiration: ⤷  Try a Trial

Patent: 6008462
Estimated Expiration: ⤷  Try a Trial

Patent: 6831716
Estimated Expiration: ⤷  Try a Trial

Patent: 7056751
Estimated Expiration: ⤷  Try a Trial

Patent: 2125884
Estimated Expiration: ⤷  Try a Trial

Patent: 4989139
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 01792
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0171477
Estimated Expiration: ⤷  Try a Trial

Patent: 0181737
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 19474
Estimated Expiration: ⤷  Try a Trial

Patent: 21017
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 51918
Estimated Expiration: ⤷  Try a Trial

Patent: 21171
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 13012770
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 51918
Estimated Expiration: ⤷  Try a Trial

Patent: 21171
Estimated Expiration: ⤷  Try a Trial

Patent: 53708
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 1300153
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 41845
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 6474
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 16752
Estimated Expiration: ⤷  Try a Trial

Patent: 13545812
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 51918
Estimated Expiration: ⤷  Try a Trial

Patent: 21171
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 4810
Estimated Expiration: ⤷  Try a Trial

Patent: 7742
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 8210
Estimated Expiration: ⤷  Try a Trial

Patent: 13006952
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 771
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 0713
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 140698
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 51918
Estimated Expiration: ⤷  Try a Trial

Patent: 21171
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 51918
Estimated Expiration: ⤷  Try a Trial

Patent: 21171
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 99785
Estimated Expiration: ⤷  Try a Trial

Patent: 46159
Estimated Expiration: ⤷  Try a Trial

Patent: 13132947
Estimated Expiration: ⤷  Try a Trial

Patent: 16136823
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 771
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 0856
Estimated Expiration: ⤷  Try a Trial

Patent: 201510082X
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 51918
Estimated Expiration: ⤷  Try a Trial

Patent: 21171
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1303599
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 2325775
Estimated Expiration: ⤷  Try a Trial

Patent: 130130022
Estimated Expiration: ⤷  Try a Trial

Patent: 180032680
Patent: 5-클로로-N2--페닐]-피리미딘-2,4-디아민의 결정질 형태 (5--2-2--5--4--4---4[2--2--]--24- CRYSTALLINE FORMS OF 5-CHLORO-N2-2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL-N4[2-PROPANE-2-SULFONYL-PHENYL]-PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Try a Trial

Patent: 190022903
Patent: 5-클로로-N2--페닐]-피리미딘-2,4-디아민의 결정질 형태 (5--2-2--5--4--4---4[2--2--]--24- CRYSTALLINE FORMS OF 5-CHLORO-N2-2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL-N4[2-PROPANE-2-SULFONYL-PHENYL]-PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Try a Trial

Patent: 200039021
Patent: 5-클로로-N2--페닐]-피리미딘-2,4-디아민의 결정질 형태 (5--2-2--5--4--4---4[2--2--]--24- CRYSTALLINE FORMS OF 5-CHLORO-N2-2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL-N4[2-PROPANE-2-SULFONYL-PHENYL]-PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 43016
Estimated Expiration: ⤷  Try a Trial

Patent: 96526
Estimated Expiration: ⤷  Try a Trial

Patent: 05973
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 76343
Estimated Expiration: ⤷  Try a Trial

Patent: 76344
Estimated Expiration: ⤷  Try a Trial

Patent: 1307299
Estimated Expiration: ⤷  Try a Trial

Patent: 1629021
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 13000216
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZYKADIA around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1159472 ⤷  Try a Trial
Colombia 5680434 2,4-PIRIMIDINADIAMINAS UTILES EN EL TRATAMIENTO DE ENFERMEDADES NEOPLASTICAS, DESORDENES DEL SISTEMA INMUNE E INFLAMATORIOS ⤷  Try a Trial
China 112125884 制备嘧啶-2,4-二胺二盐酸盐的方法 (Method for preparing pyrimidine-2, 4-diamine dihydrochloride) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZYKADIA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2091918 1590054-1 Sweden ⤷  Try a Trial PRODUCT NAME: CERITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/15/999 20150508
2091918 15C0058 France ⤷  Try a Trial PRODUCT NAME: CERITINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/999 20150508
2091918 528 Finland ⤷  Try a Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.